Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Biomarkers & Beyond: LabConnect’s Role in Oncology Research
Tomorrow’s World Today® Podcast
21 minutes
1 month ago
Biomarkers & Beyond: LabConnect’s Role in Oncology Research
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
